SCHEMBL20013254

SCHEMBL20013254

C#CCC[C@@H](P)CCCCC

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.34
▸ LMNA P02545 3/20 0.32
▸ TSHR P16473 1/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ HTT P42858 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1324032 0.81 OPRM1 (0.48) OPRM1LMNATSHR
SCHEMBL8156276 0.78 DNM1 (0.48) OPRM1LMNATSHR
SCHEMBL11505412 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT
SCHEMBL2220069 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT
SCHEMBL5275632 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT
SCHEMBL23111414 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT
SCHEMBL11505299 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT
SCHEMBL8653866 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT
SCHEMBL5278296 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT
SCHEMBL14840112 0.78 TSHR (0.50) OPRM1LMNATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255922-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2023-08-17 — — US disclosed
US-20230255922-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2023-08-17 — — US disclosed
US-11672775-B2 Treprostinil prodrugs UNITED THERAPEUTICS CORPORATION (US) 2023-06-13 — — US disclosed
US-11672775-B2 Treprostinil prodrugs UNITED THERAPEUTICS CORPORATION (US) 2023-06-13 — — US disclosed
US-20210121433-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2021-04-29 — — US disclosed
US-20180153847-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2018-06-07 — — US disclosed
US-20180153847-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2018-06-07 — — US disclosed
WO-2018058124-A1 TREPROSTINIL PRODRUGS UNITED THERAPEUTICS CORPORATION (US) 2018-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180153847-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 OPRM1 837/4885LMNA 3503/4885TSHR 1445/4885
US-20210121433-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 OPRM1 837/4885LMNA 3503/4885TSHR 1445/4885
US-11672775-B2 Treprostinil prodrugs TYMP, TK1, DCTPP1 OPRM1 837/4885LMNA 3503/4885TSHR 1445/4885
US-20230255922-A1 TREPROSTINIL PRODRUGS TYMP, TK1, DCTPP1 OPRM1 837/4885LMNA 3503/4885TSHR 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback